<DOC>
	<DOCNO>NCT01396291</DOCNO>
	<brief_summary>This study do evaluate efficacy safety asenapine compare placebo prevent recurrence mood episode stabilization acute/manic mixed episode participant Bipolar 1 Disorder . After Screening Period , participant receive open-label asenapine match placebo 12 16 week . Participants meet stabilization criterion may randomize one two study arm ( asenapine match placebo ) receive double-blind treatment additional 26-weeks .</brief_summary>
	<brief_title>Efficacy Safety Asenapine Prevention Recurrence Mood Episodes Participants With Bipolar 1 Disorder ( P06384 )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Asenapine</mesh_term>
	<criteria>Inclusion criterion : Male , female childbearing potential nonpregnant , nonlactating , use medically accept method contraception . Each participant must willing able provide write informed consent . Each participant must identify external contact person identify responsible person . Current diagnosis Bipolar 1 Disorder , current manic ( Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision [ DSMIVTR^TM ] code 296.4x ) mixed ( DSMIV code 296.6x ) episode determine structured clinical interview ( Mini International Neuropsychiatric Interview [ MINI ] ) Screening . Each participant must confirm experience acute manic mixed bipolar 1 episode . Exclusion criterion : Uncontrolled , unstable clinically significant medical condition . Clinically significant abnormal laboratory , vital sign , physical examination , electrocardiogram finding Screening . Current primary Axis I disorder bipolar 1 disorder . Meets current DSMIVTR^TM criterion substance abuse dependence ( exclude nicotine ) . Imminent risk selfharm harm others .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>